Medicap Healthcare Files ₹240 Crore IPO to Increase Pharma Packaging Capacity and Pay Down Debt

Mumbai, 23 September 2025: Medicap Healthcare Limited has submitted its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise ₹240 crore through an initial public offering (IPO). The whole issue consists of fresh equity shares, with a buffer for a pre-IPO placement of up to ₹48 crore, which will be deducted from the size of the total issue. The company is targeting a listing at both BSE and NSE.

Based out of its facility at GIDC Manjusar, Vadodara-based Medicap Healthcare is a manufacturer of critical packaging products for pharmaceutical companies like Euro Head caps and bottle preforms. The company supplies both domestic as well as international pharma customers. Its planned listing on Indian stock exchanges is an attempt to increase its capacity as well as widen its balance sheet.

IPO Filing of ₹240 Crore to be Utilized for Expansion and Debt Repayment

The IPO will be utilized on various strategic fronts. Medicap Healthcare has planned to utilize ₹74.37 crore for acquiring new plant and machinery, including 29 injection moulding machines and allied utilities, to increase yearly production by almost 966 million units.

Apart from this, ₹32.90 crore will also go towards repayment or pre-payment of borrowings, and ₹52.80 crore will be utilized in paying debt in its subsidiary company, KASR Healthcare Pvt. Ltd. The rest of the proceeds will be used for general corporate purposes within SEBI guidelines.

Revenue Rises to ₹108.3 Crore in FY25 as Profit Rises to ₹26.6 Crore

Medicap Healthcare has seen robust financials in the last three years. Operation revenue improved from ₹71.6 crore during FY23 to ₹108.3 crore during FY25, a growth of more than 51%. The profitability also moved in the same direction with the profit after tax improving from ₹14.79 crore during FY23 to ₹26.62 crore during FY25, a growth of almost 80% in two years.

EBITDA (earnings before interest, tax, depreciation and amortisation) was at ₹37.16 crore in FY25, as against ₹22.67 crore in FY23, highlighting enhanced operating efficiency. Meanwhile, the company’s net worth had grown from ₹60.32 crore in FY23 to ₹110.84 crore in FY25, while borrowings had increased sharply to ₹88.09 crore in FY25, from ₹6.98 crore in FY24, driven largely by debt for expansion.

High Promoter Holding of 98% to See Dilution Post-Issue

Presently, Medicap Healthcare is 98% held by promoters, that is, Kamalkumar Aggarwal, Rajveer Kamal Aggarwal, and Minal Aggarwal, and the remaining 2% is held by the public. With the IPO coming up, promoter holding will be diluted, opening the door for wider institutional and retail participation. The company has already engaged Aryaman Financial Services Limited as lead manager, with KFin Technologies Limited as registrar.

Key Business Reliance on Euro Head Caps Poses Concentration Risk

While the company has exhibited steady growth, its business model is not without challenges. A major proportion of its revenues is contributed by Euro Head caps, leaving it open to product concentration risks. Secondly, its whole manufacturing activity is localised in one single facility in Gujarat, increasing vulnerability to operational disruptions. Customer concentration risks and forex volatility are also faced by the company, considering it relies on imported raw materials.

Medicap Healthcare’s IPO filing is a testament to its strategic drive to increase capacity, reduce debt levels, and solidify its leadership in the pharma packaging industry. The group’s impressive revenue expansion and profitability trend over the past few years speak to operational resilience, although concentration risks and increased debt are concerns to monitor as it enters its next growth phase.

REF: https://nsearchives.nseindia.com/corporate/Registration_22092025160210_Medicap_Healthcare_Limited_DRHP.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations